How a Myelofibrosis Drug PERSISTed Through an FDA Hold

Many assumed the story of PAC for patients with myelofibrosis had ended when the FDA placed it on hold in 2016, but the release of the hold in early 2017, the publishing of PERSIST-2’s phase 3 results, and the enrolling PAC203 trial show that the story of this JAK inhibitor is far from over.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy